Role of Alprazolam in the Management of Acute Coronary Syndrome

Phase

1/2

Condition

Myocardial Ischemia

Blood Clots

Angina

Treatment

N/A

Clinical Study ID

NCT04715269

SZMC/IRB/0022

Ages 18-60
All Genders

Study Summary

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

Eligibility Criteria

Inclusion

Inclusion Criteria: Systolic BP>100mm Hg Age between 18-80 years Sinus Rhythm

Exclusion

Exclusion Criteria:

Cardiogenic Shock / Hypotension
Known Asthma/COPD
Bradycardia (HR < 60)
Already on Beta blockers/ Anxiolytics
Sick sinus syndrome
Second or third-degree heart block (in the absence of pacemaker)
Decompensated heart failure
With documented hypersensitivity to the drug or components
Valvular Heart Diseases
Congenital Heart Diseases
Status post CABG
Any co-morbidities except Diabetes Mellitus and Hypertension

Study Design

December 25, 2020

February 20, 2022

Study Description

World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to chest pain and hospital admission causing tachycardia. This study is designed to achieve the goals of lowering the heart using the anxiolytic property of alprazolam. This randomized, parallel group, close label, placebo-controlled, event driven, interventional clinical superiority study will be conducted in Cardiology department of Shaikh Zayed Hospital with a sample size of 48 allocating using lottery method in both experimental and control group. Heart Rate at baseline and after 6 hours will be monitored in both groups to establish the fall of heart rate in both patients. Data will be collected by using pre-designed performa and will be entered and analyzed via SAS 9.4. Statistical analysis will be done using T-test and p value <0.05 will be considered significant.

Significance of the study is to lower the required dosage of beta-blockers in order to achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.

Connect with a study center

Shaikh Zayed Post-Graduate Medical Institute
Lahore, 54600
Pakistan
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.